27776171|t|Analysis of Research Activity in Gastroenterology: Pancreatitis Is in Real Danger
27776171|a|Biomedical investment trends in 2015 show a huge decrease of investment in gastroenterology. Since academic research usually provides the basis for industrial research and development (R&D), our aim was to understand research trends in the field of gastroenterology over the last 50 years and identify the most endangered areas. We searched for PubMed hits for gastrointestinal (GI) diseases for the 1965-2015 period. Overall, 1,554,325 articles were analyzed. Since pancreatology was identified as the most endangered field of research within gastroenterology, we carried out a detailed evaluation of research activity in pancreatology. In 1965, among the major benign GI disorders, 51.9% of the research was performed on hepatitis, 25.7% on pancreatitis, 21.7% on upper GI diseases and only 0.7% on the lower GI disorders. Half a century later, in 2015, research on hepatitis and upper GI diseases had not changed significantly; however, studies on pancreatitis had dropped to 10.7%, while work on the lower GI disorders had risen to 23.4%. With regard to the malignant disorders (including liver, gastric, colon, pancreatic and oesophageal cancer), no such large-scale changes were observed in the last 50 years. Detailed analyses revealed that besides the drop in research activity in pancreatitis, there are serious problems with the quality of the studies as well. Only 6.8% of clinical trials on pancreatitis were registered and only 5.5% of these registered trials were multicentre and multinational (more than five centres and nations), i.e., the kind that provides the highest level of impact and evidence level. There has been a clear drop in research activity in pancreatitis. New international networks and far more academic R&D activities should be established in order to find the first therapy specifically for acute pancreatitis.
27776171	0	8	Analysis	T062	C0936012
27776171	12	29	Research Activity	T062	C0242481
27776171	33	49	Gastroenterology	T091	C0017163
27776171	51	63	Pancreatitis	T047	C0030305
27776171	82	92	Biomedical	T091	C1879848
27776171	93	103	investment	T073	C0021953
27776171	104	110	trends	T079	C1521798
27776171	131	139	decrease	T081	C0547047
27776171	143	153	investment	T073	C0021953
27776171	157	173	gastroenterology	T091	C0017163
27776171	181	189	academic	T092	C1510747
27776171	190	198	research	T062	C0035168
27776171	230	240	industrial	T057	C0021267
27776171	241	265	research and development	T062	C0035170
27776171	267	270	R&D	T062	C0035170
27776171	299	307	research	T062	C0035168
27776171	308	314	trends	T079	C1521798
27776171	331	347	gastroenterology	T091	C0017163
27776171	365	370	years	T079	C0439234
27776171	427	433	PubMed	T170	C1138432
27776171	443	473	gastrointestinal (GI) diseases	T047	C0017178
27776171	519	527	articles	T170	C0282420
27776171	533	541	analyzed	T062	C0936012
27776171	610	618	research	T062	C0035168
27776171	626	642	gastroenterology	T091	C0017163
27776171	684	701	research activity	T062	C0242481
27776171	745	751	benign	T080	C0205183
27776171	752	764	GI disorders	T047	C0017178
27776171	779	787	research	T062	C0035168
27776171	805	814	hepatitis	T047	C0019158
27776171	825	837	pancreatitis	T047	C0030305
27776171	848	853	upper	T082	C1282910
27776171	854	865	GI diseases	T047	C0017178
27776171	887	892	lower	T082	C0441994
27776171	893	905	GI disorders	T047	C0017178
27776171	938	946	research	T062	C0035168
27776171	950	959	hepatitis	T047	C0019158
27776171	964	969	upper	T082	C1282910
27776171	970	981	GI diseases	T047	C0017178
27776171	1022	1029	studies	T062	C2603343
27776171	1033	1045	pancreatitis	T047	C0030305
27776171	1050	1057	dropped	T081	C0205216
27776171	1074	1078	work	T062	C0035168
27776171	1086	1091	lower	T082	C0441994
27776171	1092	1104	GI disorders	T047	C0017178
27776171	1109	1114	risen	T081	C0205217
27776171	1144	1163	malignant disorders	T047	C0442867
27776171	1175	1180	liver	T191	C0345904
27776171	1182	1189	gastric	T191	C0024623
27776171	1191	1196	colon	T191	C0699790
27776171	1198	1208	pancreatic	T191	C0235974
27776171	1213	1231	oesophageal cancer	T191	C0546837
27776171	1291	1296	years	T079	C0439234
27776171	1307	1315	analyses	T062	C0936012
27776171	1342	1346	drop	T081	C0205216
27776171	1350	1367	research activity	T062	C0242481
27776171	1371	1383	pancreatitis	T047	C0030305
27776171	1421	1428	quality	T080	C0332306
27776171	1436	1443	studies	T062	C2603343
27776171	1466	1481	clinical trials	T062	C0008976
27776171	1485	1497	pancreatitis	T047	C0030305
27776171	1503	1513	registered	T058	C1514821
27776171	1537	1547	registered	T058	C1514821
27776171	1548	1554	trials	T062	C0008976
27776171	1560	1571	multicentre	T062	C0206012
27776171	1576	1589	multinational	T078	C1512888
27776171	1606	1613	centres	T073,T093	C0475309
27776171	1618	1625	nations	T083	C0454664
27776171	1678	1684	impact	T080	C4049986
27776171	1689	1703	evidence level	T033	C0393009
27776171	1728	1732	drop	T081	C0205216
27776171	1736	1753	research activity	T062	C0242481
27776171	1757	1769	pancreatitis	T047	C0030305
27776171	1775	1797	international networks	T064	C0870735
27776171	1811	1819	academic	T092	C1510747
27776171	1820	1834	R&D activities	T062	C0035170
27776171	1884	1891	therapy	T169	C0039798
27776171	1909	1927	acute pancreatitis	T047	C0001339